Eva Pharma announced that the drug "remdesivir" has obtained a new license based on scientific studies conducted on the drug, and it showed the effectiveness of the drug in accelerating the recovery of patients infected with the emerging corona virus, not only in critical cases, but also in simple and moderate cases.
The company added in a statement that the new approval did not allow the use of "remdesivir" for cases outside hospitals, and stressed the importance of using the drug under medical supervision.
And the US Food and Drug Administration "FDA", one of the major global scientific references in the field of the world of medicine, has expanded its license for emergency use of "remdesivir", to include all adults and children infected with the new Corona virus in hospitals, regardless of the severity of their disease symptoms.
The previous scientific estimates issued by the "authority", which were adopted by the rest of the world that had access to the "drug", had allowed the use of "remdesivir" for Corona patients with severe cases only, and the "American Authority" defined them as patients with low levels Blood oxygen, or they need oxygen therapy or ventilator.
The American agency said, in a recent report issued by it, that the known and potential benefits of "remdesivir" outweigh the known and potential risks.
The approval to expand the use of the anti-viral drug comes, based on scientific studies conducted by the American National Institute of Allergy and Infectious Diseases on 1062 patients with "Corona", which showed an acceleration of the recovery and recovery period from "Corona" for mild and moderate cases, if using "remdesivir", to become 10 Only days, instead of 15 days.
And the study on the drug concluded that the number of deaths in patients with Corona who were treated with "remdesivir" decreased to less or equal to 2 percent, during the various studies conducted on it.
Egypt is considered one of the first countries in the world to benefit from the drug "Ramdesivir", which is produced by Eva Pharma, among the first 3 factories in the world that worked on the production of the drug, in partnership with the global company Gilead Sciences.
The head of the scientific committee to confront the new Corona virus at the Egyptian Ministry of Health, Hossam Hosni, had confirmed a few days ago that the results of using "remdesivir" in Egypt were positive, and similar to the global results.
Hosni expected that the World Health Organization would expand the indications for using the drug in the next stage, for its benefit for patients with mild and moderate cases.
Managing Director of "Eva Pharma", Riyad Armanious, affirmed his company's commitment to providing the needs of the Egyptian state and more than 100 countries around the world with "Ramdesiver Eva Pharma".
"Armanius" said, in a press statement today, that the results of using "Ramdisiver Eva Pharma" around the world have reduced the need for ventilators and hospital care.
The Source: skynewsarabia.com
The Source: skynewsarabia.com
Sections :
Health